DEF 14A: OrthoPediatrics Corp. Announces Details for 2024 Annual Stockholders Meeting

OrthoPediatrics Corp. will hold its 2024 annual meeting of stockholders on May 24, 2024, to elect directors, approve executive compensation, adopt an incentive award plan, and ratify the appointment of its independent auditor.

Summary

• OrthoPediatrics Corp. is holding its 2024 annual meeting of stockholders on May 24, 2024, at The St.
• Louis Club in St.
• Louis, Missouri.
• The purposes of the meeting include electing three directors to serve until the 2027 annual meeting, approving executive compensation on an advisory basis, approving the OrthoPediatrics Corp. 2024 Incentive Award Plan, and approving the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for determining stockholders eligible to vote at the meeting is April 4, 2024.
• The company will commence sending a Notice of Internet Availability of Proxy Materials on or about April 12, 2024.
• Stockholders can vote over the Internet or by mail.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company is taking steps to improve corporate governance and ESG practices, which is a positive sign.

Positives

• The company is providing stockholders with multiple options for voting, including online and by mail.
• The Board is actively engaged in corporate governance and risk oversight.
• The company has an ESG team reporting to the Corporate Governance Committee.
• The company has a clawback policy in place.
• The company encourages diversity and inclusion.

Risks

• The advisory votes on executive compensation and auditor appointment are non-binding.
• If a quorum is not present, the annual meeting may be adjourned.
• The company's future performance and stock value are subject to market risks.

Future Outlook

The company expects to continue to increase its disclosures and communicate its ESG efforts in future SEC filings.

Management Comments

• The Board recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as the Company continues to grow.
• We believe effectively managing our priorities, as well as increasing our transparency related to ESG programs, will help create long-term value for our stakeholders.

Industry Context

The company operates in the medical device industry, which is highly regulated and competitive. The company's performance is influenced by factors such as technological advancements, regulatory changes, and market demand for pediatric orthopedic solutions.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the company's focus on ESG and corporate governance aligns with best practices in the medical device industry.
• Companies like Zimmer Biomet and Stryker are also focused on ESG and corporate governance.

Corporate Governance

Related Party Transactions

• The company has supply relationships with Structure Medical, LLC, which is owned by Squadron Capital LLC.
• The company has a license arrangement with Vilex, LLC, a wholly-owned subsidiary of Squadron Capital LLC.
• The company has a mortgage note payable to Tawani Enterprises Inc., the owner of which is a member of Squadron's Managing Committee.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
• Employees may be affected by the approval of the 2024 Incentive Award Plan.
• The company's ESG efforts may impact customers, suppliers, and the broader community.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its annual meeting on May 24, 2024.
• The company will continue to implement its ESG initiatives and report on its progress in future filings.

Key Dates

Keywords

annual meeting, proxy statement, directors, executive compensation, incentive award plan, Deloitte & Touche LLP, stockholders, corporate governance, OrthoPediatrics